Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

AlphaRx Outsources Hepatitis Drug Manufacturing to Venturepharm

publication date: Dec 18, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AlphaRx signed a long-term contract manufacturing agreement with Venturepharm. Under the agreement, Venturepharm will supply AlphaRx with the API for its experimental hepatitis drug ARX1088. ARX1088 is an oral interferon inducer that AlphRx is testing as an adjunct to standard interferon regimens. The company hopes to market the drug eventually in China and other emerging markets. Terms of the agreement were not disclosed. More details...

Stock Symbol: (OTCBB: ALRX)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...